Ozone Therapy for Fibromyalgia: What the Evidence Says in 2026

At a Glance

Fibromyalgia sits at an awkward intersection of chronic pain medicine and integrative care. Conventional pharmacology offers modest benefit — duloxetine, milnacipran, and pregabalin achieve roughly 30–50% responder rates in trials, and many patients tolerate them poorly. Against that backdrop, ozone therapy has accumulated a credible if still-thin evidence base that warrants serious clinical attention.

The best evidence so far is two small randomised trials. In Sucuoğlu 2023 (54 patients, autohemotherapy added to usual care, placebo-controlled), fatigue, “feel good” and sleep scores improved more with ozone, but the main outcome, the FIQ total score, did not differ from placebo (PMID 36530072). In Hou 2025 (66 patients, double-blind, ozonated versus plain water enema, one centre in Shanghai), pain, anxiety and sleep scores improved more with ozone (PMID 39903016). Neither result has been replicated, and the two trials used different routes.

Why Fibromyalgia Is a Plausible Target for Ozone

Fibromyalgia is no longer considered a purely psychological or musculoskeletal condition. Convergent evidence points to a neuroimmune substrate: central sensitization, glial activation in the dorsal horn and brain, elevated pro-inflammatory cytokines (IL-6, IL-8, TNF-α), mitochondrial dysfunction in muscle tissue, and autonomic dysregulation. Each of those pathways maps onto known ozone mechanisms.

Central Sensitization and Neuroinflammation

The hallmark of fibromyalgia is central sensitization — an upward gain-setting in spinal and supraspinal pain processing. Neuroinflammatory mediators, particularly glial-derived cytokines, sustain that sensitization. Ozone therapy at therapeutic concentrations (20–40 μg/mL for systemic routes) produces a brief, controlled reactive oxygen species (ROS) burst that activates the Nrf2 pathway, upregulating heme oxygenase-1 (HO-1) and glutathione synthesis. The downstream effect is a reset of the redox environment, suppression of NF-κB-driven cytokine transcription, and reduced IL-6 and TNF-α output from peripheral macrophages and — indirectly — from spinal microglia.

This hormetic mechanism is the same one that governs response across other inflammatory conditions, but fibromyalgia’s neuroinflammatory substrate makes it a particularly logical target.

Mitochondrial and Muscle Oxygenation

Muscle biopsies in fibromyalgia patients consistently show mitochondrial ultrastructural abnormalities and reduced Complex I/II activity. Ozone improves erythrocyte deformability and stimulates 2,3-DPG synthesis, increasing oxygen off-loading at the tissue level. In practice, patients frequently report that the post-session fatigue lift precedes the pain reduction by several weeks — consistent with a mitochondrial/oxygenation mechanism acting before the anti-inflammatory one consolidates.

Autonomic Tone

Fibromyalgia is characterized by sympathetic overdrive and attenuated parasympathetic recovery. Rectal insufflation in particular appears to engage vagal afferents through the enteric nervous system. Several observational reports note heart rate variability (HRV) improvements after ozone courses that parallel subjective wellbeing gains — a mechanistic thread worth formal prospective study but already clinically observable.

What the Trials Show

Randomized Controlled Evidence

Beyond these two trials, the published data are small observational series and reviews.

Observational and Mechanistic Studies

Proposed mechanisms, such as oxidative preconditioning and cytokine changes, come from laboratory and small observational work and have not been linked to outcomes in controlled trials.

Patient Selection: Who Is Likely to Respond

No trial has tested who responds best. The profile below is a hypothesis drawn from mechanism, not from trial data:

Favorable indicators:

• Elevated baseline inflammatory markers (CRP > 1.0, IL-6 > 10 pg/mL, ferritin disproportionately elevated)
• Significant fatigue component (fatigue VAS ≥ 6/10): predicts the mitochondrial/oxygenation pathway is operative
• Post-infectious onset or overlap with chronic infection (Lyme, EBV, CMV)
• Poor response to or intolerance of SNRIs/pregabalin but retained sensitivity to physical interventions (exercise, TENS)
• Autonomic features: POTS-like symptoms, poor sleep architecture on wearable tracking

Less favorable or requiring additional evaluation:

• Purely somatic/psychiatric presentation with no inflammatory markers: the redox mechanism has less to engage
• Active hyperthyroidism (ozone is relatively contraindicated)
• Established G6PD deficiency (absolute contraindication for all systemic ozone routes)
• Severe coagulopathy or thrombocytopenia
• Pregnancy

The inflammatory-phenotype distinction is a plausible screening idea, not a validated one: patients with normal IL-6, CRP, and ferritin who have fibromyalgia primarily through central sensitization without systemic inflammation are the lowest-probability responders in the mechanistic data.

Delivery Routes and Protocol Details

Rectal Insufflation

Not tested in a randomised fibromyalgia trial so far (the 2025 trial used an ozonated-water enema, a different preparation). Typically 200–400 mL gas at 20–40 μg/mL ozone concentration, administered per-rectally after bowel preparation. Absorbed through the rectal mucosa into the portal circulation; reaches systemic levels within minutes. Well-tolerated with minimal discomfort when the patient has emptied the bowel beforehand. The main advantage is that it achieves systemic ozone exposure without venous access — relevant for patients with needle aversion or difficult IV access. Starting concentration 20 μg/mL, titrating to 40 μg/mL by session 4–5.

Major Autohemotherapy (MAH)

200–400 mL autologous blood is drawn into an ozone-tolerant bag, mixed with ozone gas (typically 40–60 μg/mL), and re-infused intravenously over 20–30 minutes. Achieves higher peak plasma ozone concentrations than rectal insufflation. Sucuoğlu 2023 used major and minor autohemotherapy as an add-on, twice weekly for 10 sessions. Requires trained clinical staff and a dedicated ozone generator.

Ozonated Saline IV

Ozone dissolved in normal saline, infused IV. Lower ozone delivery per session than MAH but technically simpler. Used in some observational fibromyalgia protocols as part of a combined IV therapy suite. Evidence base in fibromyalgia specifically is thinner; mostly inferred from the systemic ozone mechanism literature.

Typical Course Structure

For fibromyalgia, a 10–20 session induction course delivered 2–3× per week is common in published protocols. The 2023 autohemotherapy trial used 10 sessions over five weeks. Whether maintenance sessions after the induction course help has not been studied.

Integrating Ozone Into a Multimodal Fibromyalgia Protocol

Ozone therapy does not replace the evidence-based pillars of fibromyalgia management. The combination with aerobic exercise and sleep hygiene intervention produces better outcomes than any single modality alone in cohort data. A rational integration looks like:

Foundation: Graded aerobic exercise (pool or low-impact), sleep architecture optimization, dietary anti-inflammatory approach (Mediterranean pattern, reduced ultra-processed foods)

Pharmacologic adjuncts if needed: Low-dose naltrexone (LDN) for neuroinflammatory phenotype, low-dose amitriptyline for sleep, duloxetine if mood-pain co-morbidity present

Ozone therapy layer: 10–20 session induction course during the first 8–12 weeks, using rectal insufflation as first-line (lower barrier; no trial has compared routes), MAH for patients with clear inflammatory biomarker elevation or poor response to rectal route after 5–6 sessions

Monitoring: FIQ total score and NRS pain at baseline, week 4, and end of course. IL-6 and CRP at baseline to identify inflammatory phenotype; recheck at course end as a response biomarker. HRV tracking if patient uses a wearable.

There is no established responder rate for ozone in fibromyalgia. Two small trials point in a positive direction, mainly on secondary outcomes. That justifies discussing it as an experimental adjunct, not ranking it against approved medicines.

Safety Profile in the Fibromyalgia Context

The two fibromyalgia trials were too small to characterise safety. Minor effects commonly described in ozone practice are transient bloating with rectal insufflation (resolving within 30–60 minutes) and occasional mild dizziness during MAH re-infusion (typically rate-related and resolved by slowing infusion).

The G6PD deficiency contraindication is absolute and applies regardless of route — ozone’s ROS mechanism is lethal to G6PD-deficient erythrocytes. Screen all patients with a G6PD assay before first treatment. This is a simple, inexpensive blood test and should be routine in any ozone practice.

Fibromyalgia patients often have significant treatment anxiety and somatic hypervigilance. The pre-session conversation should explicitly frame the expected mild sensations (warmth during re-infusion, brief bloating) so they are not misinterpreted as adverse effects, which can otherwise trigger nocebo responses that confound outcomes.

Related Articles

• Ozone Therapy Evidence: What the Clinical Research Actually Shows — broad mechanistic and evidence overview across indications
• Ozone Therapy Risks: A Physician’s Honest Assessment: full contraindication list and route-specific risk stratification
• Ozone vs IV Laser Therapy: A Head-to-Head Comparison: when to choose each modality
• Ozone Therapy for Lyme Disease: application to post-Lyme and chronic infection syndromes
• Low-Dose Naltrexone: Mechanisms and Clinical Use: complementary neuroinflammatory approach often combined with ozone in fibromyalgia